Industry Veteran brings over 30 years of experience in drug development JERUSALEM, Jan. 31, 2018 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ:  NTEC) (TASE:  NTEC ), a clinical stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary Accordion

JERUSALEM, January 8, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced it has entered into a Feasibility and Option agreement with

JERUSALEM, January 3, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill TM  platform technology, today announced that the Canadian Intellectual Property Office has issued

· Closed equity offering of $57.5 million; Cash of $64.7 million at September 30, 2017 · Expanding planned enrollment to 420 patients in its Phase 3 ACCORDANCE Trial; enrollment to be completed in the third quarter of 2018 · Formed new U.S. Medical Affairs and U.S.

JERUSALEM, November 8, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced that Jeffrey Meckler, Chief Executive Officer, will provide a

JERUSALEM, November 1, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced that Mr. Zvi Joseph, founder and Mr. Giora Carni, former CEO of

JERUSALEM, October 26, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC) (TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced it has named Mr. Walt Linscott to the position of Chief

JERUSALEM, October 6, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in the Oppenheimer Specialty Pharma Summit to be held October 11, 2017 at the Sofitel Hotel in New York City. Date:   Wednesday, October 11, 2017 Venue:  Sofitel New

JERUSALEM, September 20, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in the Ladenburg Thalmann 2017 Healthcare Conference to be held September 26, 2017 at the Sofitel Hotel in New York City.

JERUSALEM, September 8, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in the 19th Annual Rodman & Renshaw Global Investment Conference to be held September 10-12, 2017 at the Lotte New York Palace Hotel in New York City.